Tag:
Folotyn
Latest Headlines
Latest Headlines
Spectrum nabs Allos buyout as bladder cancer drug fails PhIII
Spectrum Pharmaceuticals ($SPPI) put on the best face possible on the news that its bladder cancer drug apaziquone failed two late stage studies.
Allos inks $360M Folotyn pact as cancer drug sales disappoint
After disappointing analysts with its sales numbers for Folotyn, Allos Therapeutics ( $ALTH ) turned around and announced an ex-North American licensing pact for the drug which will deliver $50 million
$30K per month: Too much for a cancer drug?
How much is too much to pay for a cancer drug? New York Times healthcare writer Andrew Pollack examines the case of Folotyn, Allos Therapeutics' recently-approved cancer drug. Folotyn is indicated
FDA approves Allos' cancer drug
Allos Therapeutics' shares were up 8 percent on the news that the FDA had approved Folotyn for use as a single agent for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). It's
